Thompson Rahsaan sold $438K of ZVRA
Thompson Rahsaan (Chief Legal & Compliance) sold 34,557 shares of ZEVRA THERAPEUTICS, INC. (ZVRA) at $12.68 ($0.44M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale size, price, and post-transaction holdings; it can influence near-term sentiment but does not change fundamentals in the text.
Market read
Insider selling under a 10b5-1 plan is usually a low-signal event; any trading impact is likely limited to short-term sentiment.
What to watch
Traders may over-weight insider sales; without changes in guidance, trials, or financing, the disclosure is typically sentiment-only.
Background
The article is an SEC Form 4 insider transaction filing for ZEVRA THERAPEUTICS, Inc.
Ticker impact
SEC Form 4 shows Thompson Rahsaan (Chief Legal & Compliance) sold 34,557 ZVRA shares for about $438.3K on 2026-06-22 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted and short-lived.
The filing is a pre-arranged 10b5-1 open-market sale by an officer, with no accompanying new operational/regulatory/financial information.
Market effects
Minimal—this is company-specific insider transaction data, not a sector-wide signal.
None.
None.
Counterpoint
Because it’s a 10b5-1 plan, the sale may be mechanically scheduled and less informative than discretionary selling.
Key entities
- issuerZEVRA THERAPEUTICS, INC.
Subject of the Form 4 insider transaction disclosure.
- insiderThompson Rahsaan
Chief Legal & Compliance officer who sold shares under a pre-arranged 10b5-1 plan.
